Author:
Vicente Jose,Johannesen Lars,Hosseini Meisam,Mason Jay W.,Sager Philip T.,Pueyo Esther,Strauss David G.
Funder
U.S. Food and Drug Administration
Publisher
Public Library of Science (PLoS)
Reference34 articles.
1. ICH. ICH Topic S7B The nonclinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 2005.
2. ICH. Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2005 [11/10/2015]. 61134]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf.
3. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?;N Stockbridge;Drug Saf,2013
4. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties;C Antzelevitch;Circulation,2004
5. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone;L Wu;Cardiovascular research,2008
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献